Compare VAL & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAL | ACLX |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.2B |
| IPO Year | N/A | 2022 |
| Metric | VAL | ACLX |
|---|---|---|
| Price | $60.34 | $68.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $52.14 | ★ $115.50 |
| AVG Volume (30 Days) | 850.5K | ★ 1.1M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.61 | N/A |
| Revenue | ★ $2,416,000,000.00 | $35,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $302.49 |
| P/E Ratio | $10.77 | ★ N/A |
| Revenue Growth | ★ 6.81 | N/A |
| 52 Week Low | $27.15 | $47.86 |
| 52 Week High | $61.70 | $94.07 |
| Indicator | VAL | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.14 | 33.01 |
| Support Level | $55.90 | $66.00 |
| Resistance Level | $61.21 | $75.03 |
| Average True Range (ATR) | 2.34 | 5.23 |
| MACD | 0.32 | -1.69 |
| Stochastic Oscillator | 82.55 | 12.96 |
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.